Arformoterol Tartrate Solution
Product Images NDC 72266-259

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Arformoterol Tartrate (NDC 72266-259). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fosun Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

30 Vial Carton Label (30s Carton Label)

30 Vial Carton Label (30s Carton Label)
Description: This is a 30-pack carton of Arformoterol Tartrate Inhalation Solution for oral inhalation use. The potency is expressed as arformoterol. It is recommended to keep the solution refrigerated or at room temperature for up to 6 weeks. It is important to keep this medication out of reach of children. The product is manufactured by Fosunpharma.*
FDA Label Image

4vial Pouch (4units Pouch)

4vial Pouch (4units Pouch)
FDA Label Image

60 Vial Carton Label (60s Carton Label)

60 Vial Carton Label (60s Carton Label)
Description: The text appears to be related to a 60-pack carton containing Arformoterol Tartrate Inhalation Solution. The carton includes important information such as the potency description, instructions for use, and contact details for inquiries. It is essential to keep the product out of reach of children and to follow the specified instructions for proper usage.*
FDA Label Image

Figure (Aformoterol 01)

Figure (Aformoterol 01)
FDA Label Image

Figure 1 (Aformoterol 02)

Figure 1 (Aformoterol 02)
This text shows the mean change from baseline Forced Expiratory Volume in one second (FEV1) for a study comparing a placebo group to a group using 15 mcg of arformoterol tartrate taken twice daily. The baseline FEV1 for the placebo group was 1.20 L and for the arformoterol group was 1.15 L. Measurements were taken at various hours post-dose.*
FDA Label Image

Figure 2 (Aformoterol 03)

Figure 2 (Aformoterol 03)
Mean change from baseline Forced Expiratory Volume in one second (FEV1) was evaluated in a study comparing a placebo group (n=143) with a group receiving 15 mcg of arformoterol tartrate twice a day (n=141). Baseline FEV1 for the placebo group was 1.20 liters, and for the arformoterol tartrate group, it was 1.15 liters. The changes in FEV1 over time were examined postdose.*
FDA Label Image

Figure 1 (Aformoterol 05)

Figure 1 (Aformoterol 05)
FDA Label Image

Figure 2 (Aformoterol 06)

Figure 2 (Aformoterol 06)
FDA Label Image

Figure 3 (Aformoterol 07)

Figure 3 (Aformoterol 07)
FDA Label Image

Figure 4 (Aformoterol 08)

Figure 4 (Aformoterol 08)
FDA Label Image

Figure 5 (Aformoterol 09)

Figure 5 (Aformoterol 09)
FDA Label Image

Figure 6 (Aformoterol 10)

Figure 6 (Aformoterol 10)
FDA Label Image

Single Vial Pouch Label (Single Pouch)

Single Vial Pouch Label (Single Pouch)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.